Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis

被引：3

作者：

Hatanaka, Takeshi ^{[1
]}

Kakizaki, Satoru ^{[2
,3
]}

Hiraoka, Atsushi ^{[4
]}

Tada, Toshifumi ^{[5
]}

Hirooka, Masashi ^{[6
]}

Kariyama, Kazuya ^{[7
]}

Tani, Joji ^{[8
]}

Atsukawa, Masanori ^{[9
]}

Takaguchi, Koichi ^{[10
]}

Itobayashi, Ei ^{[11
]}

Fukunishi, Shinya ^{[12
]}

Tsuji, Kunihiko ^{[13
]}

Ishikawa, Toru ^{[14
]}

Tajiri, Kazuto ^{[15
]}

Ochi, Hironori ^{[16
]}

Yasuda, Satoshi ^{[17
]}

Toyoda, Hidenori ^{[17
]}

Ogawa, Chikara ^{[18
]}

Nishimura, Takashi ^{[19
]}

Shimada, Noritomo ^{[20
]}

Kawata, Kazuhito ^{[21
]}

Kosaka, Hisashi ^{[22
]}

Naganuma, Atsushi ^{[23
]}

Yata, Yutaka ^{[24
]}

Tanaka, Takaaki ^{[4
]}

Ohama, Hideko ^{[4
]}

Tada, Fujimasa ^{[4
]}

Nouso, Kazuhiro ^{[7
]}

Morishita, Asahiro ^{[8
]}

Tsutsui, Akemi ^{[10
]}

Nagano, Takuya ^{[10
]}

Itokawa, Norio ^{[9
]}

Okubo, Tomomi ^{[9
]}

Arai, Taeang ^{[9
]}

Imai, Michitaka ^{[14
]}

Koizumi, Yohei ^{[6
]}

Nakamura, Shinichiro ^{[5
]}

Kaibori, Masaki ^{[22
]}

Iijima, Hiroko ^{[19
]}

Hiasa, Yoichi ^{[6
]}

Kumada, Takashi ^{[25
]}

机构：

[1] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Japan

[2] Natl Hosp Org, Dept Clin Res, Takasaki Gen Med Ctr, Takasaki, Japan

[3] Gunma Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Maebashi, Japan

[4] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan

[5] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Japan

[6] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Matsuyama, Japan

[7] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[8] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Japan

[9] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[10] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Japan

[11] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[12] Osaka Med & Pharmaceut Univ, Premier Dept Res Med, Osaka, Japan

[13] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan

[14] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[15] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[16] Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Japan

[17] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[18] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Japan

[19] Hyogo Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Nishinomiya, Japan

[20] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Japan

[21] Hamamatsu Univ, Dept Internal Med 2, Hepatol Div, Sch Med, Hamamatsu, Japan

[22] Kansai Med Univ, Dept Surg, Hirakata, Japan

[23] Natl Hosp Org, Dept Gastroenterol, Takasaki Gen Med Ctr, Takasaki, Japan

[24] Hanwa Mem Hosp, Dept Gastroenterol, Osaka, Japan

[25] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

来源：

HEPATOLOGY RESEARCH | 2023年 / 53卷 / 08期

关键词：

antibiotic; atezolizumab; bevacizumab; gut microbiome; hepatocellular carcinoma; immune checkpoint inhibitor; proton pump inhibitor; MICROBIOME; EFFICACY; ALTER;

D O I：

10.1111/hepr.13905

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: This retrospective study aimed to investigate the impact of proton pump inhibitor treatment (PPI) and antibiotic treatment on the therapeutic outcomes of hepatocellular carcinoma (HCC) patients receiving atezolizumab and bevacizumab (Atez/Bev). Methods: The present study included a total of 441 HCC patients who were treated with Atez/Bev in 20 Japanese institutions from September 2020 to April 2022. We adopted the inverse probability of treatment weight to adjust for imbalance in the baseline characteristics of patients with and without PPI treatment as well as patients with and without antibiotic treatment. Results: The progression-free survival (PFS) and overall survival (OS) of patients with and without PPI treatment did not differ to a statistically significant extent. In the weighted cohort, the difference in PFS and OS between the patients with and without PPI did not reach statistical significance (median PFS, 7.0 vs. 6.5 months, p = 0.07; 1-year survival rate 66.3% and 73.8%, p = 0.9). The PFS and OS in patients with antibiotic treatment were worse in comparison to patients without antibiotic treatment (median PFS, 3.8 vs. 7.0 months, p = 0.007; 1-year survival rate 58.8% and 70.3%, p = 0.01). In the weighted cohort, the PFS and OS of the two groups did not differ to a statistically significant extent (median PFS, 3.8 vs. 6.7 months, p = 0.2; 1-year survival rate, 61.8% and 71.0%, p = 0.6). Conclusions: The therapeutic outcomes of Atez/Bev in HCC patients did not differ between patients with and without PPI treatment or between patients with and without antibiotic treatment.

引用

页码：737 / 748

页数：12

共 50 条

[31] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
Chon, Young Eun
Cheon, Jaekyung
Kim, Hyeyeong
Kang, Beodeul
Ha, Yeonjung
Kim, Do Young
Hwang, Seong Gyu
Chon, Hong Jae
Kim, Beom Kyung
CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
[32] Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Fukuokaya, Wataru
Egawa, Shin
EUROPEAN UROLOGY, 2021, 79 (04) : 553 - 554
[33] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
Linbin Lu
Peichan Zheng
Yan Pan
Shanshan Huang
Erqian Shao
Yan Huang
Xuewen Wang
Yayin Chen
Gongbao Cuo
Hongyi Yang
Wangting Guo
Yanhong Shi
Zhixian Wu
Xiong Chen
British Journal of Cancer, 2023, 129 : 620 - 625
[34] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
Lu, Linbin
Zheng, Peichan
Pan, Yan
Huang, Shanshan
Shao, Erqian
Huang, Yan
Wang, Xuewen
Chen, Yayin
Cuo, Gongbao
Yang, Hongyi
Guo, Wangting
Shi, Yanhong
Wu, Zhixian
Chen, Xiong
BRITISH JOURNAL OF CANCER, 2023, 129 (04) : 620 - 625
[35] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[36] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
LIVER CANCER, 2024, 13 (05) : 522 - 536
[37] Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis
Hatanaka, Takeshi
Saito, Naoto
Kakizaki, Satoru
Hiraoka, Atsushi
Tada, Toshifumi
Kariyama, Kazuya
Tani, Joji
Takaguchi, Koichi
Itobayashi, Ei
Ishikawa, Toru
Toyoda, Hidenori
Kawata, Kazuhito
Naganuma, Atsushi
Yata, Yutaka
Ohama, Hideko
Matono, Tomomitsu
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Nakamura, Shinichiro
Kumada, Takashi
ONCOLOGY, 2025, 103 (02) : 94 - 106
[38] ASSOCIATION OF PROTON PUMP INHIBITOR USE WITH RENAL OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE
Gil, Hyo-Wook
Cho, Nam-Jun
Park, Samel
Lee, Eun-young
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
[39] Association of proton pump inhibitor use with renal outcomes in patients with coronary artery disease
Cho, Nam-Jun
Choi, Chi-Young
Park, Samel
Park, Sang-Ho
Lee, Eun Young
Gil, Hyo-Wook
KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (01) : 59 - 68
[40] Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients- multicenter analysis
Hiraoka, Atsushi
Kumada, Takashi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kaibori, Masaki
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Iijima, Hiroko
Kosaka, Hisashi
Hiasa, Yoichi
Kudo, Masatoshi
LIVER CANCER, 2023, 12 (03) : 209 - 217

← 1 2 3 4 5 →